Browsing Category
Seppic
Tablet ejection: A systematic comparison between force, static friction, and kinetic friction
The magnitude of the frictional forces during the ejection of porous pharmaceutical tablets plays an important role in determining the occurrence of tabletting defects. Here, we perform a systematic comparison between the maximum ejection force, static friction coefficient, and kinetic friction…
Read More...
Read More...
Multi-component mixing and demixing model for predictive finite element modelling of pharmaceutical…
A set of numerical methods is described that allows predictive finite element method (FEM) simulations of the compaction of multi-component pharmaceutical powder formulations across the entire range of compositions. An automated parametrisation procedure was used to extract density-dependent…
Read More...
Read More...
Formulating pharmaceutical topical dosage forms with high level of solvents and minimal quantity of…
Poster presented by Gattefosse and RCPE at the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology, 18 - 21 March 2024, Vienna, Austria:
INTRODUCTION
Some APIs are very challenging to formulate. This is the case for example when the drug has limited…
Read More...
Read More...
Acrylic co-polymer and organic acid-based press coated pulsatile tablet of nifedipine using 32…
Many diseases exhibit circadian fluctuation, including diabetes, asthma, rheumatoid arthritis, and hypertension. These disorders cannot be effectively treated with conventional dosage forms and instead require time-scheduled drug release for pharmacological effectiveness.
The objective of this…
Read More...
Read More...
QbD Based Formulation Development and Optimisation of Ozenoxacin Topical Nano-Emulgel and Efficacy…
To formulate and optimize Ozenoxacin nano-emulsion using Quality by Design (QbD) concept by means of Box–Behnken Design (BBD) and converting it to a gel to form Ozenoxacin nano-emulgel followed by physico-chemical, in-vitro, ex-vivo and in-vivo evaluation. This study demonstrates the application of…
Read More...
Read More...
Vitafoods Geneva 2024 – with a focus on excipients
This year Vitafoods Europe opens its doors for the last time in Geneva at Palexpo.
From 14th to 16th May you can have a face-to-face chat with visitors and exhibitors again.
Pharma Excipients gives you an overview of the excipient suppliers, their booths, main topics and products in the…
Read More...
Read More...
SEPPIC Introduces SEPINEO P 600 Polymer for Topical Application
SEPINEO™ P 600 is multifunctional: thickening, emulsifying, stabilizing and texturing agent. Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer/Isohexadecane & Polysorbate 80. Ready-to-use, it is designed for the formulation such as gels and creams and is very easy to implement.
SEPINEO™ P…
Read More...
Read More...
High mobility group box 1 cytokine targeted topical delivery of resveratrol embedded nanoemulgel for…
Resveratrol is a polyphenolic compound showing anti-inflammatory activity by inhibition of high mobility group box 1 cytokine responsible for the activation of nuclear factor-κB pathway in atopic dermatitis. To evaluate the efficacy of resveratrol through topical route we have developed…
Read More...
Read More...
Development of solid lipid microparticles (SLMs) containing asiatic acid for topical treatment of…
Solid lipid microparticles (SLMs) represent a promising approach for drug delivery in anti-acne applications. In this study, asiatic acid-loaded SLMs (AASLMs) were prepared by melt emulsification method in conjunction with freeze-drying. Comprehensive evaluations comprised particle size, %entrapment…
Read More...
Read More...
SEPITRAP™ offers new possibilities for formulation and improving the bioavailability of active…
Description
SEPITRAP™ is a micro-encapsulated solubilizer in powder form designed to simplify the manufacturing of solid oral form drugs. It is manufactured by adsorption of the solubilizer in liquid form on a porous support.
SEPITRAP™ is both a solid solubilizer and a compression agent.…
Read More...
Read More...